Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rezatapopt - PMV Pharmaceuticals

Next Previous
Drug Profile

Rezatapopt - PMV Pharmaceuticals

Alternative Names: PC-14586; PC-586

Latest Information Update: 04 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PMV Pharmaceuticals
  • Developer M. D. Anderson Cancer Center; PMV Pharmaceuticals
  • Class Alkynes; Amines; Anisoles; Antineoplastics; Benzamides; Fluorinated hydrocarbons; Indoles; Piperidines; Small molecules
  • Mechanism of Action Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 19 Jan 2026 PMV Pharmaceuticals plans a phase I Drug-Drug interaction study trial for Solid tumours (Late-stage disease, Metastatic disease) in US (PO, Tablets) (NCT07372625)
  • 24 Oct 2025 Efficacy and adverse events data from the phase-I/II PYNNACLE trial in Solid tumours released by PMV Pharmaceuticals
  • 22 Oct 2025 Efficacy and adverse events data from the phase-I/II PYNNACLE trial in Solid tumours presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025 (AACR-NCI-EORTC-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top